Microcap Ledger Humacyte, Inc. $HUMA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Durham, NC
- Fiscal year end
- December 31
- Shares outstanding
- 277,798,105 [10-Q 2026-08-12]
What the company doesAI summary of filing
Humacyte, Inc. is a commercial-stage biotechnology company that develops and manufactures acellular tissue engineered vessels (ATEVs), bioengineered human tissues designed for vascular repair and reconstruction. The company received FDA approval in December 2024 for Symvess (its ATEV product) for extremity arterial injury repair and commenced U.S. commercial launch in the first quarter of 2025. Humacyte generates revenue from product sales and is also conducting Phase 3 clinical trials in additional indications including arterial-venous access for hemodialysis. The company operates an 83,000 square foot manufacturing facility using proprietary technology to produce ATEVs at commercial scale. [10-K 2026-03-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $901.0K | −$54.42M | −$47.16M | $79.90M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $2.04M | −$40.83M | −$105.04M | $50.50M | [10-K 2026-03-27] |
| FY ended Dec 2024 | $0.00 | −$148.70M | −$98.12M | $44.94M | [10-K 2026-03-27] |
- Quarterly cash burn
- −$23.58M
- Cash runway Estimate
- ~10.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 125,859,496 | [10-Q 2024-11-08] |
| 2025-03-27 | 155,118,816 | [10-K 2025-03-31] |
| 2025-05-05 | 155,118,816 | [10-Q 2025-05-13] |
| 2025-08-04 | 158,372,173 | [10-Q 2025-08-11] |
| 2025-11-04 | 187,271,321 | [10-Q 2025-11-12] |
| 2026-03-24 | 222,019,108 | [10-K 2026-03-27] |
| 2026-05-11 | 222,019,108 | [10-Q 2026-05-13] |
| 2026-08-10 | 277,798,105 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2025-09-12; declared effective 2025-09-22 [S-3 2025-09-12]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-31. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-31 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-31] |
| 2026-05-08 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-05-08] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-14 | Jones Keith Anthony | buy | 10,000 | $0.56 | [4 2026-09-15] |
| 2026-08-20 | Jones Keith Anthony | buy | 10,000 | $0.69 | [4 2026-08-21] |
| 2026-08-17 | Jones Keith Anthony | buy | 30,000 | $0.59 | [4 2026-08-19] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-08-18 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations |
| 2026-07-31 | 8-K | Listing notice or transfer |
| 2026-07-28 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-13 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-22 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-15 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-11 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-06-11 | 424B5 | Prospectus or prospectus supplement |
| 2026-06-10 | 424B5 | Prospectus or prospectus supplement |
Alerts for $HUMA
Email me when Humacyte, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.